GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

Showing 73-84 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedSupporting evidence

Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework.

Kaczynski MM; Zureikat RM; Kaczynski MR; Sitarz R; Karakuła-Juchnowicz H

Jan 1, 2026Biomedicines

2026PubMedDirectly related

Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass.

Mera-Carreiro S; Ramos-Leví A; Matía-Martín P; Bernaldo-Madrid B; Rodríguez-Carrillo C; Marcuello-Foncillas C; Pérez-Ferre N; Torres-García A; Sánchez-Pernaute A; Esteban-López-Jamar JM; Rubio-Herrera MÁ

Jan 1, 2026Obesity surgery

2026PubMedDirectly related

EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy.

European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)

Jan 1, 2026Journal of hepatology

2026PubMedSupporting evidence

The effectiveness of digital therapeutics in improving sleep quality: a systematic review and network meta-analysis.

Tong Z; Ye G; Fan S; Li Y; Zhang J; Zhang H; Chen Q; Wang H; Li H; Wang J

Jan 1, 2026BMC medicine

2026PubMedDirectly related

Skeletal Muscle Effects of GLP 1 Receptor Agonists: Molecular Mechanisms and Comparative Insights on Semaglutide and Tirzepatide, a Narrative Review.

Cautela D; Incarbona V; Lombardi A; Laratta B; Castaldo CM; Balestrieri ML; Mocini E; Migliaccio S; Tardito D

Jan 1, 2026International journal of molecular sciences

2026PubMedDirectly related

GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Pediatric Obesity: From Neuroendocrine Mechanisms to Clinical Application.

Myśliwczyk D; Myśliwiec M; Minarowska A; Wasilewska E

Jan 1, 2026International journal of molecular sciences

2026PubMedDirectly related

GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework.

Kaltsas A; Gkioxaris V; Giannakas T; Zachariou A; Dimitriadis F; Sofikitis N; Chrisofos M

Jan 1, 2026Journal of clinical medicine

2026PubMedDirectly related

Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.

Enache V; Popescu DC; Marcu B; Diaconu M; Nechita AC

Jan 1, 2026Medicina (Kaunas, Lithuania)

2026PubMedDirectly related

Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk.

Roach KA; Khazaee M; Mohar I; Boon D; Cronin B; Gauthier AG

Jan 1, 2026Regulatory toxicology and pharmacology : RTP

2026PubMedSupporting evidence

Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome.

Ravić MP; Srejović IM; Andjić MM; Murić MD; Sretenović JZ; Jeremić NS; Milosavljević IM; Vuletić ML; Murić NN; Ravić KR; Bolevich SB; Sergeeva SP; Gorbunov AA; Bolevich SS; Jakovljević VL; Novaković JN

Jan 1, 2026Medical sciences (Basel, Switzerland)

2026PubMedSupporting evidence

Renal outcomes in people with type 2 diabetes with and without albuminuria treated with SGLT-2 inhibitors and GLP-1 receptor agonists: target trial emulation.

Turchin A; Petito LC; Hegermiller E; Chelliah I; Carnahan RM; DeVries A; Goel S; Lansang MC; McDonnell ME; Nair V; Priest E; Willey VJ; Kaul AF; Hernán MA; BESTMED collaborating investigators

Jan 1, 2026BMJ (Clinical research ed.)

2026PubMedDirectly related

Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes.

Lin CL; Lin KC; Yu JM; Chang CL; Lin YY; Fang CY; Chen WM; Wu SY

Jan 1, 2026Nature communications